Online GLP-1 scams persist despite federal penalties
A telehealth network that once paid $5 million to settle US government allegations of deceptive GLP-1 sales is still drawing complaints from customers who say they never received their orders or were charged for products they never received.
The company operates websites offering compounded versions of GLP-1 medications, which are in high demand for weight loss and diabetes management. Multiple buyers have taken to social media to describe orders that vanished after payment, repeated billing cycles, and unresponsive customer service that left them out of pocket and without treatment. Regulators previously faulted the network for misleading marketing and billing practices, yet fresh reports suggest the problems continue.
A familiar pattern of refunds and renewals
The recurring complaints center on automatic subscription renewals that customers say are difficult to cancel, alongside shipments that either arrive late or not at all. Some purchasers only discovered the issue after checking credit-card statements weeks later, when unauthorized charges appeared. Despite the earlier $5 million settlement, the company remains active, prompting questions about the effectiveness of penalties in deterring repeat offenses.
Why compounded GLP-1s raise red flags
Compounded medications are not FDA-approved and can carry additional safety risks when obtained from unverified online sources. Health authorities have warned that these products may be substandard, contaminated, or improperly dosed. The telehealth network’s compounded GLP-1s fall outside standard regulatory pathways, amplifying concerns for patients seeking reliable treatment options.
Source: Wired. AI-assisted editorial synthesis — TechnoExpress.